Cga clinical trials

Explore recruiting cga clinical trials.

Recruiting cga studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Cga trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

CDX0159-08: A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Barzolvolimab (CDX-0159) in Adults with Active Eosinophilic Esophagitis (The “EvolvE” Study)

Spain, Germany, Poland, Italy

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 2, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study with an Extension to Investigate the Efficacy and Safety of Solrikitug in Adults with Eosinophilic Esophagitis (ALAMERE)

Belgium, Poland, Spain, Italy, Netherlands

Therapeutic exploratory (Phase II) EU CTIS Study details

A Randomized, Double-Blinded, Placebo-Controlled, Phase 2, Parallel-Group Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Efgartigimod PH20 SC in Adult Participants With Systemic Sclerosis

Lithuania, Bulgaria, Croatia, France, Portugal, Hungary +10 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase II, randomised, placebo-controlled, double-blind, parallel-group, efficacy and safety study of at least 48 weeks of oral BI 685509 treatment in adults with progressive systemic sclerosis

Spain, Denmark, France, Austria, Belgium, Netherlands +11 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Multicenter, Randomized, Parallel-group, Double-blind, Two-arm, Phase III Study to Evaluate the Safety and Efficacy of Anifrolumab Compared with Placebo in Male and Female Participants 18 to 70 Years of Age Inclusive with Systemic Sclerosis

Austria, Poland, Hungary, Romania, Spain, Germany +4 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Trial title: Phase 1b/3 global, randomized, controlled, open-label trial comparing treatment with RYZ101 to standard of care (SoC) therapy in subjects with inoperable, advanced, somatostatin receptor expressing (SSTR+), well-differentiated gastro-enteropancreatic neuroendocrine tumors (GEP-NETs) that have progressed following prior 177Lu-labelled somatostatin analogue (177Lu-SSA) therapy (ACTION-1)

Spain, France, Netherlands, Belgium

Therapeutic confirmatory (Phase III) EU CTIS Study details

Cga trials by city

Cga in Toronto Cga in Vancouver Cga in Montreal Cga in Calgary Cga in Edmonton Cga in Ottawa Cga in Winnipeg Cga in Quebec City Cga in Hamilton Cga in Kitchener Cga in London Cga in Halifax Cga in New York Cga in Los Angeles Cga in Chicago Cga in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease